No abstract

The aim of this study was to evaluate the role of HSP70, and markers of oxidative stress and endothelial dysfunction, as determinants of the severity of coronary atherosclerosis. The study revealed significant differences between patient groups with and without coronary atherosclerosis in terms of HSP70, superoxide dismutase, total homocysteine (tHcy) and markers of oxidative modification of proteins. Significant correlations between Gensini score, lipid profile parameters and studied markers were determined. The results of multiple linear regression analysis allow us to consider the levels of HSP70, tHcy, LDL-C and ketone derivative of 2.4-dinitrophenylhydrazine as factors associated with the risk of coronary atherosclerosis.

This study reports an assessment of adaptive possibilities of the central nervous system (CNS) in infants. The study shows how the homocysteine level depends on the severity of neurological deficit (ND) in infants, and how the serum homocysteine level changes during the various treatment regimens. (International Journal of Biomedicine. 2017;7(4):286-288.)

Results of this study present the features of the severity of coronary atherosclerosis, evaluated by the Gensini score, depending on the use of statins. Differences in indicators of oxidative stress, inflammation and endothelial dysfunction are revealed. In addition, the study established the relationship between statin intake and studied biomarkers and revealed the features of changes in the studied markers, depending on the achievement of the target levels of total cholesterol and LDL-C.

The aim of the study was to evaluate the effectiveness of sodium deoxyribonucleate (spray) in the treatment of patients with acute respiratory infections (ARI) in the outpatient setting. Materials and Methods: We conducted a randomized controlled clinical trial. The study included 112 patients aged from 18 to 73 years with an established diagnosis of ARI and a duration of symptoms of the disease no more than 48 hours. The investigational drug-a 0.25% solution of sodium deoxyribonucleate (SD) for external and topical use (spray bottle, 10 ml). Group 1 included 54 patients who received SD: 2 intranasal doses into each nostril every 1-1.5 hours during the first days of the onset of the ARI symptoms; then-2 doses into each nostril 3 times per day against the background of symptomatic therapy for 5 days. Symptomatic therapy included decongestants, antipyretics, mucolytics and antitussives (if necessary). Group 2 included 58 patients who received only symptomatic therapy. Medical examination was performed daily for 5 days. Results: Including a 0.25% SD spray solution in the ARI treatment regimen effectively affects the dynamics of the ARI symptoms. SD in the treatment scheme from the first day allows eliminating the main ARI symptoms much faster and more efficiently than the standard treatment regimen; in particular, recovery is accelerated by 2-3 days. Complex therapy including SD causes a 3-fold increase in the level of sIgA in the nasal mucosa of patients on the fifth day of treatment, which indicates a pronounced immunomodulating effect of this intervention, a potential reduction in the risk of complications and recurrence of viral diseases.